Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CIT | O14578 | 6/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TPH1 | P17752 | 5/20 | 0.40 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.39 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.36 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.36 |
| ▸ | LTA4H | P09960 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30167503 | 1.00 | CIT (0.45) | CITALDH1A1TPH1ITGA4ITGB7 | |
| SCHEMBL539489 | 1.00 | CIT (0.45) | CITALDH1A1TPH1ITGA4ITGB7 | |
| Hydrochloric Acid SCHEMBL539490 | 0.99 | CIT (0.45) | CITALDH1A1TPH1ITGA4ITGB7 | |
| Hydrochloric Acid SCHEMBL539367 | 0.99 | CIT (0.45) | CITALDH1A1TPH1ITGA4ITGB7 | |
| Hydrochloric Acid SCHEMBL31206084 | 0.99 | CIT (0.45) | CITALDH1A1TPH1ITGA4ITGB7 | |
| SCHEMBL26706405 | 0.87 | CIT (0.42) | CITTPH1PDCD1CD274 | |
| SCHEMBL26706360 | 0.86 | KDM4E (0.40) | CITALDH1A1ITGA4ITGB7KDM4E | |
| SCHEMBL24073155 | 0.86 | SLC7A5 (0.49) | CITTPH1PTGS2KDM4EPDCD1 | |
| SCHEMBL28948045 | 0.86 | SLC7A5 (0.49) | CITTPH1PTGS2KDM4EPDCD1 | |
| Hydrochloric Acid SCHEMBL29106517 | 0.85 | SLC7A5 (0.48) | TPH1PTGS2KDM4EPDCD1CD274 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115667268-A | Preparation method of GLP-1 receptor agonist free base | 杭州中美华东制药有限公司 | 2023-01-31 | — | — | CN | claimed |
| CN-115667268-A | Preparation method of GLP-1 receptor agonist free base | 杭州中美华东制药有限公司 | 2023-01-31 | — | — | CN | disclosed |
| WO-2021242806-A1 | INTERMEDIATES AND METHODS FOR PREPARING A GLP-1 RECEPTOR AGONIST | VTV THERAPEUTICS LLC (US) | 2021-12-02 | — | — | WO | disclosed |
| US-9175003-B2 | Substituted azoanthracene derivatives and intermediates for preparation thereof | VTV THERAPEUTICS LLC (US) | 2015-11-03 | — | — | US | disclosed |
| EP-2413693-B1 | SUBSTITUTED AZOANTHRACENE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | VTV THERAPEUTICS LLC (US) | 2015-09-09 | — | — | EP | disclosed |
| US-20150148539-A1 | Substituted Azoanthracene Derivatives and Intermediates for Preparation Thereof | VTV THERAPEUTICS LLC | 2015-05-28 | — | — | US | disclosed |
| US-8987295-B2 | Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof | TRANSTECH PHARMA, LLC (US) | 2015-03-24 | — | — | US | disclosed |
| US-20130096150-A1 | Substituted Azoanthracene Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof | TRANSTECH PHARMA, INC. (US) | 2013-04-18 | — | — | US | disclosed |
| US-8383644-B2 | Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof | TRANSTECH PHARMA, INC. (US) | 2013-02-26 | — | — | US | disclosed |
| WO-2010114824-A1 | SUBSTITUTED AZOANTHRACENE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | TRANSTECH PHARMA INC (US) | 2010-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130096150-A1 | Substituted Azoanthracene Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof | GLP1R, GIPR, GPR119 | CIT 2336/4885ALDH1A1 1899/4885TPH1 1016/4885 |
| US-20150148539-A1 | Substituted Azoanthracene Derivatives and Intermediates for Preparation Thereof | GLP1R, GIPR, GPR119 | CIT 2873/4885ALDH1A1 737/4885TPH1 485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.